Killing you slowly so you can live again
For generations, sickle cell disease has quietly shaped the boundaries of entire lives — what could be attempted, endured, or hoped for. In Bellevue, Nebraska, a twenty-one-year-old named Martin Mwita has become one of the first Americans to cross a new threshold, receiving FDA-approved gene therapy that has begun replacing the disease's cruel geometry with something closer to ordinary possibility. His story arrives at a moment when medicine is learning to rewrite inherited suffering, though the path remains steep, costly, and not yet open to all who need it.
- A young man who spent his childhood defined by strokes, hospitalizations, and monthly blood exchanges now wakes up without sickle cell pain for the first time in his life.
- The treatment — a $3.1 million procedure requiring intensive chemotherapy that stripped his skin, silenced his voice, and left him isolated for months — tested the limits of what a body and a family can endure.
- Insurance approval came through for Martin, but the staggering cost and grueling process mean that this breakthrough remains out of reach for most of the patients who need it most.
- His fourteen-year-old sister Abigail, who also carries the disease and has survived brain aneurysms, has already begun the evaluation process and received insurance approval — the therapy's promise moving quietly through one family.
- Nebraska Medicine is in active talks to bring gene therapy local, and researchers are working to reduce chemotherapy burdens and costs, pushing toward a future where this treatment is not a rare exception but a genuine option.
Martin Mwita came home to Bellevue in May, five months after a procedure that has fundamentally changed what his future might look like. At twenty-one, he is among the first Americans to receive one of two FDA-approved gene therapies for sickle cell disease — a condition that has shaped nearly every corner of his life since he suffered strokes and serious lung blockages at eighteen months old.
The disease warps red blood cells into rigid crescents that block blood vessels and trigger pain episodes lasting for days. For Martin, hospitalizations became routine, then monthly red blood cell exchanges at Nebraska Medical Center. He didn't talk about it much. He just wanted to be a regular kid.
When the FDA approved two gene therapies in October 2023 — Lyfgenia, made by Bluebird Bio, and Casgevy, from Vertex Pharmaceuticals — Martin became the first patient to receive Lyfgenia at St. Louis Children's Hospital. The process required his own stem cells to be extracted, corrected in a laboratory with a healthy hemoglobin gene, and returned to his body. Getting there meant months of medical testing, an insurance battle, and a six-and-a-half-hour drive to St. Louis. The treatment costs $3.1 million — a figure his family's insurance ultimately covered, though many will not be so fortunate.
The chemotherapy required to prepare his bone marrow was its own ordeal. His skin peeled. Sores covered his mouth and throat until he couldn't eat or speak. His mother, Jacinta, called it "killing you slowly so you can live again." Martin got through it with music — the Beatles, Billy Joel — his faith, and a scrapbook assembled by family and friends when he hit bottom.
He was infused with his corrected cells in mid-March and discharged by early April. His body now produces roughly fifty-four percent normal red blood cells, a figure expected to reach one hundred percent over time. He hasn't experienced sickle cell pain since. He plays golf and pickleball, hangs out with friends, and lives without the constant vigilance against heat, cold, and dehydration that once governed his days.
The months of isolation that followed — his immune system still fragile while the world moved on around him — were their own quiet trial. He filled the time watching sports and posting movie reviews online. His doctors have advised against returning to the University of Nebraska at Omaha this fall, and they continue monitoring his organs for any lasting effects of the chemotherapy.
His sister Abigail, fourteen, who also has sickle cell and has survived brain aneurysms, has begun the evaluation process for the same therapy and recently received insurance approval. She just made the varsity cheer team at Bellevue East High School. Nebraska Medicine is working toward offering gene therapy locally, already in talks with Vertex about providing Casgevy. Researchers are exploring ways to reduce the chemotherapy burden and lower costs to reach more patients.
Martin, who once kept his illness private, is now willing to speak about it. "There's hope," he said, "and they can get through it." His mother looks further still. "I believe there's a plan for him to do something with his life," Jacinta said, "and I hope he achieves it."
Martin Mwita came home to Bellevue in May, five months after undergoing a procedure that has fundamentally altered the trajectory of his life. At twenty-one, he is among the first Americans to receive one of two newly approved gene therapies for sickle cell disease—a treatment that has already begun rewriting what his future might hold.
For most of his life, sickle cell has been the defining constraint. The genetic mutation that causes it warps red blood cells into rigid crescents that jam together in blood vessels, blocking flow and triggering pain episodes that can last for days. At eighteen months old, Martin suffered strokes and serious blockages in his lungs. His mother, Jacinta, nearly lost him. The hospitalizations that followed became routine—so routine that she stopped counting them. He received blood transfusions regularly, then monthly red blood cell exchanges at Nebraska Medical Center starting in 2016. The disease dictated what he could do, where he could go, who he could be. He didn't talk about it much. He just wanted to be a regular kid.
Then, in October 2023, the FDA approved two gene therapies for sickle cell patients twelve and older. Lyfgenia, made by Bluebird Bio, works by extracting a patient's own blood-making stem cells, inserting a healthy hemoglobin gene into them in a laboratory, and returning the corrected cells to the body. Casgevy, from Vertex Pharmaceuticals, uses a different genetic editing approach. Martin became the first patient to receive Lyfgenia at St. Louis Children's Hospital, where pediatric hematologist Shalini Shenoy oversees the program.
The path to treatment was neither simple nor quick. Jacinta had to navigate extensive medical testing to ensure Martin could physically and mentally withstand the process, then fight for insurance approval. The treatment itself costs $3.1 million—a staggering sum, though Martin's medical bills in a single bad year have equaled that amount. His insurance approved coverage. Not all families will be as fortunate.
Late last year, the Mwitas drove six and a half hours to St. Louis. Martin received an infusion of medication to coax his stem cells from bone marrow into his bloodstream, then spent three days in a chair, up to six hours at a time, while technicians collected the cells—eventually filling a container the size of a mini Coca-Cola can. A helicopter transported them to the biotech firm, where scientists inserted the healthy gene. When the cells returned to St. Louis in spring, Martin underwent five days of intensive chemotherapy to clear space in his bone marrow for the engineered cells to take root. His skin peeled. He vomited. Sores covered his mouth and throat until he couldn't eat or speak. His mother called it "killing you slowly so you can live again." He got through it by listening to music—the Beatles, Billy Joel—and drawing on his faith. A hospital volunteer gave him a memoir about the Beatles. The volunteer's wife made him a glass angel. When he hit bottom, his mother presented a scrapbook his family and friends had assembled.
Martin was infused with his corrected cells in mid-March. By early April, he was discharged. After another month of monitoring in an apartment near the hospital, he and his mother returned home on May 9. His body is now producing approximately fifty-four percent normal red blood cells, a figure expected to reach one hundred percent over time. He hasn't experienced sickle cell pain. He can hang out with friends at home, play golf and pickleball outdoors, and live without the constant vigilance against dehydration, heat, and cold that once governed his days.
The isolation that followed was its own kind of trial. With his immune system still fragile, Martin spent months largely alone while his mother returned to work and his twin siblings attended school. He filled the time watching basketball playoffs, March Madness, the Masters, and an "exorbitant amount of movies," posting reviews on Letterboxd. It was like a COVID lockdown, but only for him. His doctors have advised against returning to the University of Nebraska at Omaha this fall, where he had been studying business, and they continue monitoring his organs closely for any lingering damage from the chemotherapy.
His sister Abigail, fourteen, who also has sickle cell and has suffered brain aneurysms, has now begun the evaluation process for the same therapy and recently received insurance approval. She just made the varsity cheer team at Bellevue East High School. Nebraska Medicine, which has treated Martin's family for years, is working toward offering gene therapy locally—currently in talks with Vertex about providing Casgevy. The hospital already offered its first gene therapy for hemophilia, a different genetic bleeding disorder, last fall. Researchers are exploring ways to reduce the chemotherapy burden, lower costs, and expand access. For now, Martin is willing to share his story, something he once avoided. "There's hope," he said, "and they can get through it." His mother looks further ahead still. "I believe there's a plan for him to do something with his life," Jacinta said, "and I hope he achieves it."
Citações Notáveis
It was really cool. In many regards, it was a medical marvel.— Martin Mwita, on receiving the gene therapy
There's hope and that they can get through it.— Martin Mwita, on sharing his story with others facing sickle cell disease
A Conversa do Hearth Outra perspectiva sobre a história
What made Martin's case suitable for this therapy when so many others with sickle cell might not be?
His organs were in surprisingly good shape despite years of transfusions and complications. That matters because the chemotherapy is brutal—your body has to be strong enough to survive it. And his family had the resources and insurance support to navigate a process that's still new and complicated.
The cost is staggering. Three point one million dollars. How does that sit with you?
It's the reality of cutting-edge medicine right now. His mother said their medical bills in a single bad year equaled that amount anyway. But not every family has insurance that will cover it. That's the gap researchers are trying to close.
He spent months isolated after coming home, even though he was supposedly recovering well. That sounds psychologically brutal.
It was. His immune system was still too fragile for normal life. He couldn't go to classes, couldn't be around crowds. So he watched sports and movies alone in an apartment, then alone at home. The physical ordeal of chemotherapy was one thing. The mental weight of isolation was another.
His sister is now in the pipeline for the same treatment. Does that change the family's calculus?
Absolutely. They've seen Martin's results. She's already approved for coverage. But his mother is careful to say this isn't for everyone—not everyone will be as good a candidate, not everyone will have outcomes this positive. It's still experimental in the sense that long-term data is limited.
What does Martin want now that the disease isn't controlling his life?
He's more willing to talk about it, which is new for him. He spent years not wanting to be defined by sickle cell. Now he sees value in sharing his story, in giving hope to others going through it. But he's also just a college student who wants to study business and live a normal life. The therapy gave him that possibility back.